SCYNEXIS Announces Its Phase 1 Trial Of Intravenous Formulation Of SCY-247 To Treat Invasive Fungal Infections Showed Intravenous Doses Of 50 Mg Or Higher Achieved Exposures At Or Above Target Identified In Murine Models Of Invasive Candidiasis
SCYNEXIS, Inc. (NASDAQ: SCYX) ("SCYNEXIS", or the "Company"), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced topline results
Share
Why It Matters
SCYNEXIS tested a new medicine for serious fungal infections. The medicine worked well enough in early human tests to move forward.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.